Update shared on03 Oct 2025
Fair value Increased 5.05%Analysts have raised their price target for Artivion by approximately $2.14 to $44.54. This change is based on constructive feedback from cardiac surgeons, positive incremental clinical updates, and ongoing confidence in the company’s growth prospects.
Analyst Commentary
Recent updates from various analysts have highlighted a range of factors influencing Artivion's outlook and stock valuation. The following sections summarize the key bullish and bearish perspectives that are shaping sentiment on the company.
Bullish Takeaways- Bullish analysts have raised their price targets, citing continued confidence in the strength of Artivion’s business fundamentals and clinical progress.
- Incremental product and clinical updates, especially around advanced stent grafts and the On-X platform, are viewed as supporting the company's growth narrative.
- Positive comments from multiple cardiac surgeons on utilization trends and future publication of favorable data are believed to be driving greater acceptance in the broader cardiac surgery community.
- Consistent EBITDA growth and margin improvements reinforce Artivion's positioning as a dependable operator with potential for upside in the coming years.
- Some bearish analysts have shifted to a more neutral stance and express caution even as they increase price targets, due to perceived risks in execution and expectations management.
- Concerns persist around the pace at which broader clinical acceptance and adoption can translate into meaningful financial performance improvements.
- Competitive dynamics and near-term visibility into major growth drivers remain areas of scrutiny for those maintaining less constructive views.
What's in the News
- Artivion has raised its earnings guidance for 2025, with a new expected constant currency revenue growth of 12% to 14%, up from the prior 11% to 14% range. (Company Guidance)
- The company now forecasts reported revenues for 2025 in the range of $435 to $443 million. This is compared to the previous outlook of $423 to $435 million, as the company cites a strong second quarter and improved FX assumptions. (Company Guidance)
- Full year 2025 currency impact is currently estimated to be approximately flat compared to 2024. This provides clarity on revenue growth expectations. (Company Guidance)
Valuation Changes
- Consensus Analyst Price Target has increased from $42.40 to $44.54, reflecting a moderate upward adjustment in fair value estimates.
- Discount Rate has decreased slightly from 7.75% to 7.66%, indicating a marginally lower perceived risk in the valuation model.
- Revenue Growth expectation remains virtually unchanged at 12.16%.
- Net Profit Margin projection is stable, holding at 6.54%.
- Future P/E ratio has risen from 80.90x to 84.79x, suggesting increased expectations for future earnings growth relative to current share price.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.